Jeffrey L. Lennox, MD

Jeffrey L. Lennox, MD

Emory University School of Medicine

Professor of Medicine and Associate Dean for Clinical Research
Emory University
Vice Chair for Grady Affairs, Department of Medicine
Atlanta, Georgia


Committees and Organizations

  • DHHS Antiretroviral therapy guidelines panel

Honors and Awards

  • HIVMA Clinician Educator of the Year, 2008


  • B.A., Molecular, Cellular and Developmental Biology, 1975-1979
  • University of Colorado, Boulder, Colorado, M.D, 1979-1983
  • University of Colorado School of Medicine, Denver, Colorado

Selected Publications

  1. Lennox, JL,  DeJesus E, Ramalho Madruga JV, Lazzarin A, Pollard RB, Berger DS, Zhao J, Xu X,  Williams-Diaz A, Rodgers AJ, Barnard RJO,  Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P.  Safety and Efficacy of Raltegravir-based versus Efavirenz-based Combination Therapy in Treatment-Naive HIV-1 Infected Patients, Lancet, 2009, 374: 796-806
  2. Lennox, JL,  DeJesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H,  Gilbert CL, B.S.7, Teppler H, Rodgers AJ, Barnard RJO,  Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P.  Raltegravir versus Efavirenz Regimens in Treatment-Naive HIV-1 Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. J AIDS 2010, 55:39-48
  3. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na L, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn S, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS. Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1: A Randomized, Controlled Equivalence Trial. Annals of Internal Medicine 2014, 161(7):461-471.